DGAP Post-admission Duties announcement: CompuGroup Medical SE & Co. KGaA / Share Buy-back CompuGroup Medical SE & Co. KGaA: Continuation of the Share Buy-Back Program 2021-03-25 / 21:47 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Disclosure pursuant to Article 5(1)(a) of Regulation (EU) No 596/2014 and Article 3(1) of Commission Delegated Regulation (EU) No 2016/1052 Continuation of the Share Buy-Back Program Koblenz, March 25, 2021 - The increased share buy-back program announced by CompuGroup Medical SE & Co. KGaA (the "Company") in the ad-hoc release of March 25, 2021 will be continued in the period from March 26, 2021 until and including May 5, 2021 with the increased volume. With the extension of the share buy-back, the Company is again making use of the authorization granted by the annual general meeting of May 15, 2019 to purchase treasury shares pursuant to section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz) in order to buy back an additional number of up to 500,000 shares of the Company at a total purchase price of up to EUR 38,000,000.00. Including the extension of the program the total volume of the share buy-back program is up to 1,000,000 shares of the Company (corresponding to approx. 1.86% of the Company's share capital) at a total purchase price (excluding transaction costs) of up to EUR 73,000,000.00 in total (the "Share Buy-Back Program"). The Share Buy-Back Program will continue to be carried out by a credit institution. The credit institution will acquire the shares on the stock market and will decide on the timing of acquisitions independently of the Company and in accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. In addition, the purchase price per share (excluding transaction costs) paid must not exceed, or fall short of, the volume-weighted average price of the Company's share in XETRA (or a functionally comparable successor system replacing the XETRA system) trading on the Frankfurt Stock Exchange during the last five trading days before the acquisition date by more than 10%. The acquired treasury shares in CompuGroup Medical SE & Co. KGaA are to be used for purposes permitted under the authorization granted by the annual general meeting of May 15, 2019, in particular for servicing the existing stock option plans of the Company as well as the utilization as acquisition currency. The share buy-back via XETRA on the Frankfurt Stock Exchange terminates at the end of April 30, 2021, 24:00 hrs (CEST). To the extent shares in CompuGroup Medical SE & Co. KGaA shall be bought back during a closed period within the meaning of Article 19(11) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 or during a period in which CompuGroup Medical SE & Co. KGaA resolved to delay the disclosure of inside information in accordance with Article 17(4) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, CompuGroup Medical SE & Co. KGaA has continuously appointed a credit institution for the execution of these buy-backs, which will make its decisions concerning the timing of the acquisitions of the shares in CompuGroup Medical SE & Co. KGaA - in compliance with contractual obligations - independently of, and without influence by, CompuGroup Medical SE & Co. KGaA in accordance with Article 4(2)(b) of Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. CompuGroup Medical SE & Co. KGaA will not influence the decisions of the credit institution in this respect. The Share Buy-Back Program will be continue to be carried out in accordance with the safe harbor provision pursuant to Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016 and on the basis of the aforementioned authorization of the general meeting of CompuGroup Medical SE & Co. KGaA of May 15, 2019. CompuGroup Medical SE & Co. KGaA also imposed corresponding obligations on the credit institution appointed by the Company for purchasing shares in the Company. The shares in CompuGroup Medical SE & Co. KGaA will be purchased at market prices in accordance with the conditions for trading pursuant to Article 3 of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016. In particular, the shares in CompuGroup Medical SE & Co. KGaA will not be purchased at a price higher than the higher of the price of the last independent trade or the highest current independent purchase bid on the trading venue where the purchase is carried out. In addition, CompuGroup Medical SE & Co. KGaA will not purchase on any trading day more than 25% of the average daily volume of the shares on the trading venue on which the purchase is carried out. The average daily volume of shares is calculated on the basis of the average daily volume traded during the 20 trading days preceding the relevant date of purchase. Furthermore, the Share Buy-Back Program may be suspended and also resumed at any time, to the extent necessary and permitted by law. Information on transactions relating to the Share Buy-Back Program (both before and after the change) will be adequately disclosed no later than by the end of the seventh trading day following the date of execution of such transactions in a detailed form and in an aggregated form. In addition, CompuGroup Medical SE & Co. KGaA will post the disclosed transactions on its website (www.cgm.com) and ensure that the information is kept available to the public for at least five years from the date of disclosure. End Disclaimer: This publication contains forward-looking statements. These statements are based on the current views, expectations and assumptions of, and information available to, the management of CompuGroup Medical SE & Co. KGaA. Forward-looking statements do not provide a guarantee of the occurrence of future results and developments and involve known and unknown risks and uncertainties. Various factors may cause actual future results, developments or events to differ materially from those described in these statements. Neither CompuGroup Medical SE & Co. KGaA nor any other person assumes any responsibility whatsoever for the accuracy of the views expressed in this publication or the assumptions on which they are based. CompuGroup Medical SE & Co. KGaA assumes no obligation to update the forward-looking statements contained in this publication. Koblenz, March 25, 2021 CompuGroup Medical SE & Co. KGaA The general partner Contact: Investor Relations Phone +49 261 8000 7030 Email: investor@cgm.com =---------------------------------------------------------------------------------------------------------------------- 2021-03-25 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de =---------------------------------------------------------------------------------------------------------------------- Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Internet: www.cgm.com End of News DGAP News Service =------------
1178723 2021-03-25
(END) Dow Jones Newswires
March 25, 2021 16:47 ET (20:47 GMT)